Mobile

A study to examine the advantage of Sotagliflozin in addition to Insulin therapy in patients with Type 1 Diabetes Studie zkoumající výhody sotagliflozinu jako doplňku inzulinové léčby pacientů s...

Update Il y a 4 ans
Reference: EUCTR2015-001709-15

A study to examine the advantage of Sotagliflozin in addition to Insulin therapy in patients with Type 1 Diabetes Studie zkoumající výhody sotagliflozinu jako doplňku inzulinové léčby pacientů s diabetem I. typu

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To demonstrate the superiority of sotagliflozin 400 mg versus placebo in the proportion of patients with glycosylated A1C <7.0% at Week 24 and no episode of severe hypoglycemia and no episode of diabetic ketoacidosis (DKA) after randomization.

Inclusion criteria

  • Type 1 diabetes mellitus

Links